Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)

Lipids in Health and Disease

Volumn 10, Issue , 2011, Pages

  Mata, Nelva ^a   Alonso, Rodrigo ^b   Badimán, Lina ^c   Padrá, Teresa ^c   Fuentes, Francisco ^d   Mũiz, Ovidio ^e   Perez Jiménez, Francisco ^d   Lápez Miranda, José ^d   Díaz, Jose L ^f   Vidal, Jose I ^g   Barba, A ^h   Piedecausa, Mar ⁱ   Sanchez, Juan F ^j   Irigoyen, Luis ^k   Guallar, Eliseo ^l,m   Ordovas, José M ^m,n   Mata, Pedro ^b  

^a Madrid Health Authority and Fundacián Hipercolesterolemia Familiar   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f Hospital Abente y Lago   (Spain)

^g Hospital de Lugo   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^j Hospital de Caceres   (Spain)

^k Hospital de Vitoria   (Spain)

^l JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^m CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

ⁿ TUFTS UNIVERSITY   (United States)

more..

Author keywords

combined therapy; Coronary artery disease; Familial hypercholesterolemia; LDL c goal; LDL receptor mutations

Indexed keywords

ATORVASTATIN; DNA; EZETIMIBE; FLUINDOSTATIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; AZETIDINE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CROSS-SECTIONAL STUDY; DNA MICROARRAY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; SMOKING; AGED; BLOOD; DRUG COMBINATION; HEALTH SURVEY; HYPERLIPOPROTEINEMIA TYPE 2; LONGITUDINAL STUDY; MIDDLE AGED; SPAIN;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS INDICATORS; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN; SPAIN; YOUNG ADULT;

EID: 79958166529     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-10-94     Document Type: Article

References (24)

1. Familial Hypercholesterolemia. JL Goldstein HH Hobbs MS Brown, The metabolic and molecular basis of inherited disease McGraw-Hill, New York, Scriver CR, Beaudet AL, Sly WS, Valle D, 2001 II 2863 2913
2. Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. R Alonso J Defesche D Tejedor S Castillo M Stef N Mata P Gomez-Enterria C Martinez-Faedo L Forga P Mata, Clin Biochem 2009 42 899 903 10.1016/j.clinbiochem.2009.01.017 19318025
3. Familial Hypercholesterolemia. WHO Human Genetic Program, WHO/HGN/FH/CONS/98.7 Paris 1997 Report of a WHO consultation
4. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. J Slack, Lancet 1969 2 1380 2 4188273
5. The risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group, BMJ 1991 303 893 6 1933004
6. Phenotypic variation in heterozygous familial Hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. SN Pimstone XM Sun C du Souich JJ Frohlich MR Hayden AK Soutar, Arterioscler ThrombVasc Biol 1998 18 309 15 (Pubitemid 28277610)
7. Cardiovascular disease in familial hypercholesterolaemia: Influence of low-density lipoprotein receptor mutation type and classic risk factors. R Alonso N Mata S Castillo F Fuentes P Saenz O Mũiz J Galiana R Figueras JL Diaz P Gomez-Enterría M Mauri M Piedecausa L Irigoyen R Aguado P Mata, Atherosclerosis 2008 200 315 21 10.1016/j.atherosclerosis.2007.12.024 18243212
8. Phenotypic variability in familial hypercholesterolaemia: an update. AC Jansen S van Wissen J Defesche JJ Kastelein, Curr Opin Lipidol 2002 13 165 71 10.1097/00041433-200204000-00008 11891419 (Pubitemid 34280768)
9. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group, Atherosclerosis 1999 142 105 12 9920511
10. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. A Neil J Cooper J Betteridge N Capps I McDowell P Durrington M Seed SE Humphries, Eur Heart J 2008 29 2625 33 10.1093/eurheartj/ehn422 18840879
11. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. J Versmissen DM Oosterveer M Yazdanpanah JC Defesche DC Basart AH Liem J Heeringa JC Witteman PJ Lansberg JJ Kastelein EJ Sijbrands, BMJ 2008 337 2423 10.1136/bmj.a2423 19001495
12. Evaluation of cholesterol lowering treatment of patients with Familial hypercholesterolemia: A large cross-sectional study in the Netherlands. AH Piljman R Huijgen SN Verhagen BP Imholz AH Liem JJ Kastelein EJ Abbink AF Stalenhoef FL Visseren, Atherosclerosis 2010 209 189 94 10.1016/j. atherosclerosis.2009.09.014 19818960
13. WHO MONICA Project: objectives and design. S Böthig WHO MONICA Project, Int J Epidemiol 1989 18 suppl 1 29 37
14. Interpretation of SF-36 and SF-12 questionnaires in Spain: physical and mental components. G Vilagut JM Valderas M Ferrer O Garin E Lápez- García J Alonso, Med Clin (Barc) 2008 130 726 35 10.1157/13121076 (Pubitemid 351839702)
15. Using different physical activity measurements in eight European countries. Results of the European Physical Activity Surveillance System (EUPASS) time series survey. A Rütten H Ziemainz F Schena T Stahl M Stiggelbout YV Auweele J Welshman H Ziemainz, Public Health Nutr 2003 6 371 6 12795825 (Pubitemid 36749759)
16. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. WT Friedewald RI Levy DS Fredrickson, Clin Chem 1972 18 499 502 4337382
17. Cascade genetic screening for familial hypercholesterolemia. TP Leren, Clin Genet 2004 66 483 7 10.1111/j.1399-0004.2004.00320.x 15521974 (Pubitemid 39562009)
18. Familial hypercholesterolaemia: summary of NICE guidance. AS Wierzbicki SE Humphries R Minhas, BMJ 2008 337 1095 10.1136/bmj.a1095 18753174
19. Cost-efectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia. J Oliva J Lápez-Bastidas S Gutierrez P Mata R Alonso, Rev Esp Cardiol 2009 62 57 65 19150015
20. Spanish Ministry of Health, Social Policy and Equality. Spanish National Health Survey, 2006 http://www.msc.es/estadEstudios/estadisticas/ encuestaNacional/encuestaIndice2006.htm
21. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. F Civeira, Atherosclerosis 2004 173 55 68 10.1016/j.atherosclerosis.2003.11.010 15177124 (Pubitemid 38224196)
22. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. I Graham D Atar K Borch-Johnsen G Boysen G Burell R Cifkova J Dallongeville G De Backer S Ebrahim B Gjelsvik C Herrmann-Lingen A Hoes S Humphries M Knapton J Perk SG Priori K Pyorala Z Reiner L Ruilope S Sans-Menendez W Scholte op Reimer P Weissberg D Wood J Yarnell JL Zamorano E Walma T Fitzgerald MT Cooney A Dudina European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG), Eur Heart J 2007 28 2375 414 17726041 (Pubitemid 47542237)
23. Simvastatin with or without ezetimibe in familial hypercholesterolemia. JJ Kastelein F Akdim ES Stroes AH Zwinderman ML Bots AF Stalenhoef FL Visseren EJ Sijbrands MD Trip EA Stein D Gaudet R Duivenvoorden EP Veltri AD Marais E de Groot ENHANCE Investigators, N Engl J Med 2008 358 1431 43 10.1056/NEJMoa0800742 18376000 (Pubitemid 351482735)
24. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin. JS Sampalis S Bissonnette R Habib S Boukas Ezetrol Add-On Investigators, Ann Pharmacother 2007 41 1345 51 10.1345/aph.1K140 17666579 (Pubitemid 47311353)